A Phase 3 interventional study of SB-497115-GR 12.5mg and SB-497115-GR 25mg in Chronic Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-03-30.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 27th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 6th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2007, is one of 4 in phase 3, and was the 5th registered.
GlaxoSmithKline’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2005.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase II/III multicenter study comprising of the double-blind, followed by open-label phases to evaluate and compare the efficacy and tolerability of eltrombopag (SB-497115-GR) in chronic ITP patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for enrollment in the study must meet all of the following criteria.
At Screening (Week -4 or -3)
A complete blood count (CBC) within the reference range, with the following exceptions
Exclusion criteria:
Subjects meeting any of the following criteria must not be enrolled in the study.
At Screening (Week -4 or -3)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
Drug: SB-497115-GR 12.5mg · Drug: SB-497115-GR 25mg · Drug: SB-497115-GR 50 mg
Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
Drug: SB-497115-GR 12.5mg matching placebo
SB-497115-GR 12.5mg tablet once a day
SB-497115-GR 25mg tablet once a day
SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
SB-497115-GR 25mg tablet x2 once a day
Also known as: SB-497115-GR 50mg
Number of Responders at Week 6
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).
Time frame: Week 6
Percentage of Participants for Whom at Least 75% of Their Assessments During the Course of 26 Weeks of SB-497115-GR Treatment Met the Definition of Responders
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Week 26
Number of Participants Assessed as Responders in at Least 4 Assessments Between Weeks 2 and 6
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter) at at least 4 out of 5 scheduled visits.
Time frame: Weeks 2 through 6
Percentage of Responders at Each Visit
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).
Time frame: Days 8, 15, 22, 29, 36, and 43
Mean Platelet Count at Each Visit
Blood taken from peripheral blood vessels was used for the measurement of platelet counts.
Time frame: Baseline and Days 8, 15, 22, 29, 36, and 43
Mean Change From Baseline in Platelet Counts at Each Visit
Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 minus baseline value
Time frame: Baseline and Days 8, 15, 22, 29, 36, and 43
Percentage of Participants With Bleeding Episodes Since the Last Visit
When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s).
Time frame: Days 1, 8, 15, 22, 29, 36, and 43
Number of Participants at Baseline and Days 8, 15, 22, 29, 36, and 43 of Treatment by Platelet Count Category
Blood taken from peripheral blood vessels was used for the measurement of platelet counts.
Time frame: Baseline and Days 8, 15, 22, 29, 36, and 43
Percentage of Responders at Each Visit
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Mean Platelet Counts of Participants at Each Visit
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Baseline; Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Mean Change From Baseline in Platelet Counts at Each Visit
Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 and Weeks 10, 14, 18, 22, and 26 minus baseline value. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Baseline; Days 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Mean Maximum Duration for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter
Maximum duration is measured as the longest period (days) for which a participant continuously maintained platelet counts within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Weeks 1 through 26
Mean Total Time for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter
Total time is measured as the cumulative number of days over which platelet counts were maintained within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Weeks 1 through 26
Percentage of Participants With Bleeding Episode Since the Last Visit
When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Days 1, 8, 15, 22, 29, 36, and 43; Weeks 10, 14, 18, 22, and 26
Percentage of Participants With a Reduction in Dose and/or Number of Drugs of Concomitant ITP Medications From Baseline
ITP medications are drugs, such as steroids or immunoglobulin, to be used for ITP. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Baseline through Week 26
Percentage of Participants Who Received Rescue Treatment for ITP
Rescue treatment for ITP is treatment applied to participants at high bleeding risk, such as those undergoing platelet transfusion or dose increase of steroids. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Weeks 1 through 26
Mean Number of Days of Concomitant ITP Medication Use Per Month
Cumulative number of days for which a participant received ITP medication during the treatment/total treatment period (months). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
Time frame: Weeks 1 through 26
Pharmacokinetics of SB-497115-GR, Cmax
Cmax: Peak plasma concentration of SB-497115
Time frame: Week 9 or 10
Pharmacokinetics of SB-497115-GR, Tmax
tmax: Time when Cmax was achieved
Time frame: Week 9 or 10
Pharmacokinetics of SB-497115, t1/2
t1/2 is half life based on the terminal phase
Time frame: Week 9 or 10
Pharmacokinetics of SB-497115-GR, Lambda z
Lambda z is first order rate constant associated with the terminal portion of the plasma concentration curve.
Time frame: Week 9 or 10
Pharmacokinetics of SB-497115-GR, AUClast and AUC0-24
AUC is area under a concentration vs. time curve. AUC0-24 (Area under the plasma concentration-time curve between 0 to 24 hrs) is calculated using the following equation: AUC0-24= AUClast + Clast × (1 - e-λz × \[24-tlast\])/λz. AUClast is AUC (area under a curve) computed to the last observation. Clast is concentration of last observation.
Time frame: Week 9 or 10
Pharmacokinetics of SB-497115-GR, CL/F
CL/F: CL is an estimate of the total body clearance, and F is the fraction of dose absorbed.
Time frame: Week 9 or 10
Pharmacokinetics of SB-497115-GR, Vz/F
VZ/F: VZ is the volume of distribution based on the terminal phase, and F is the fraction of dose absorbed.
Time frame: Week 9 or 10
| Milestone | Placebo | SB-497115-GR, Double-blind | SB-497115-GR, Open-label |
|---|---|---|---|
| Started | 8 | 15 | 0 |
| Completed | 8 | 14 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Placebo | SB-497115-GR, Double-blind | SB-497115-GR, Open-label |
|---|---|---|---|
| Started | 0 | 0 | 22 |
| Completed | 0 | 0 | 20 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).
| Participants | SB-497115-GR | Placebo |
|---|---|---|
| Responders | 9 | 0 |
| Non-responders | 6 | 8 |
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter) at at least 4 out of 5 scheduled visits.
| Participants | SB-497115-GR | Placebo |
|---|---|---|
| Responders | 5 | 0 |
| Non-responders | 9 | 8 |
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| percentage of participants | SB-497115-GR |
|---|---|
| Percentage of Participants for Whom at Least 75% of Their Assessments During the Course of 26 Weeks of SB-497115-GR Treatment Met the Definition of Responders | 43.5 |
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter).
| Percentage of responders | SB-497115-GR | Placebo |
|---|---|---|
| Day 8 | 6.7 | 0 |
| Day 15 | 26.7 | 0 |
| Day 22 | 33.3 | 0 |
| Day 29 | 60.0 | 0 |
| Day 36 | 66.7 | 0 |
| Day 43 | 60.0 | 0 |
Blood taken from peripheral blood vessels was used for the measurement of platelet counts.
| 10^9/Liter | SB-497115-GR | Placebo |
|---|---|---|
| Baseline | 19.3 ± 6.79 | 12.6 ± 8.65 |
| Day 8 | 26.9 ± 17.77 | 14.3 ± 12.26 |
| Day 15 | 54.9 ± 55.84 | 13.5 ± 12.15 |
| Day 22 | 54.4 ± 46.88 | 11.6 ± 9.50 |
| Day 29 | 73.3 ± 46.72 | 10.6 ± 9.04 |
| Day 36 | 99.4 ± 78.62 | 11.9 ± 10.79 |
| Day 43 | 95.1 ± 100.25 | 9.9 ± 4.76 |
Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 minus baseline value
| 10^9/Liter | Placebo | SG-497115-GR |
|---|---|---|
| Day 8 | 1.6 ± 6.05 | 7.6 ± 16.47 |
| Day 15 | 0.9 ± 5.46 | 35.5 ± 56.11 |
| Day 22 | -1.0 ± 3.02 | 35.0 ± 46.52 |
| Day 29 | -2.0 ± 4.17 | 53.9 ± 46.02 |
| Day 36 | -0.8 ± 7.94 | 80.1 ± 77.06 |
| Day 43 | -2.8 ± 9.41 | 75.8 ± 99.93 |
When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s).
| Percentage of participants | SB-497115-GR | Placebo |
|---|---|---|
| Day 1 | 33 | 75 |
| Day 8 | 13 | 63 |
| Day 15 | 14 | 63 |
| Day 22 | 29 | 75 |
| Day 29 | 0 | 38 |
| Day 36 | 7 | 63 |
| Day 43 | 14 | 75 |
Blood taken from peripheral blood vessels was used for the measurement of platelet counts.
| Participants | SB-497115-GR | Placebo |
|---|---|---|
| Baseline, Platelet counts (PC) <=15 x 10^9/L | 3 | 6 |
| Baseline, PC >15 to <30 x 10^9/L | 12 | 2 |
| Baseline, PC >=30 to <=50 x 10^9/L | 0 | 0 |
| Baseline, PC =>50 to <=200 x 10^9/L | 0 | 0 |
| Baseline, PC >200 to <=400 x 10^9/L | 0 | 0 |
| Baseline, PC >400 x 10^9/L | 0 | 0 |
| Day 8, PC <=15 x 10^9/L | 3 | 5 |
| Day 8, PC >15 to <30 x 10^9/L | 6 | 2 |
| Day 8, PC >=30 to <=50 x 10^9/L | 5 | 1 |
| Day 8, PC =>50 to <=200 x 10^9/L | 1 | 0 |
| Day 8, PC >200 to <=400 x 10^9/L | 0 | 0 |
| Day 8, PC >400 x 10^9/L | 0 | 0 |
| Day 15, PC <=15 x 10^9/L | 2 | 6 |
| Day 15, PC >15 to <30 x 10^9/L | 3 | 1 |
| Day 15, PC >=30 to <=50 x 10^9/L | 5 | 1 |
| Day 15, PC =>50 to <=200 x 10^9/L | 3 | 0 |
| Day 15, PC >200 to <=400 x 10^9/L | 1 | 0 |
| Day 15, PC >400 x 10^9/L | 0 | 0 |
| Day 22, PC <=15 x 10^9/L | 3 | 5 |
| Day 22, PC >15 to <30 x 10^9/L | 3 | 3 |
| Day 22, PC >=30 to <=50 x 10^9/L | 3 | 0 |
| Day 22, PC =>50 to <=200 x 10^9/L | 5 | 0 |
| Day 22, PC >200 to <=400 x 10^9/L | 0 | 0 |
| Day 22, PC >400 x 10^9/L | 0 | 0 |
| Day 29, PC <=15 x 10^9/L | 1 | 6 |
| Day 29, PC >15 to <30 x 10^9/L | 0 | 2 |
| Day 29, PC >=30 to <=50 x 10^9/L | 4 | 0 |
| Day 29, PC =>50 to <=200 x 10^9/L | 9 | 0 |
| Day 29, PC >200 to <=400 x 10^9/L | 0 | 0 |
| Day 29, PC >400 x 10^9/L | 0 | 0 |
| Day 36, PC <=15 x 10^9/L | 2 | 7 |
| Day 36, PC >15 to <30 x 10^9/L | 0 | 0 |
| Day 36, PC >=30 to <=50 x 10^9/L | 2 | 1 |
| Day 36, PC =>50 to <=200 x 10^9/L | 9 | 0 |
| Day 36, PC >200 to <=400 x 10^9/L | 1 | 0 |
| Day 36, PC >400 x 10^9/L | 0 | 0 |
| Day 43, PC <=15 x 10^9/L | 2 | 7 |
| Day 43, PC >15 to <30 x 10^9/L | 2 | 1 |
| Day 43, PC >=30 to <=50 x 10^9/L | 1 | 0 |
| Day 43, PC =>50 to <=200 x 10^9/L | 7 | 0 |
| Day 43, PC >200 to <=400 x 10^9/L | 2 | 0 |
| Day 43, PC >400 x 10^9/L | 0 | 0 |
A responder was defined as a participant with a platelet count within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Percentage of responders | SB-497115-GR |
|---|---|
| Day 8 | 4.3 |
| Day 15 | 17.4 |
| Day 22 | 21.7 |
| Day 29 | 47.8 |
| Day 36 | 56.5 |
| Day 43 | 52.2 |
| Week 10 | 57.1 |
| Week 14 | 60.9 |
| Week 18 | 50.0 |
| Week 22 | 52.4 |
| Week 26 | 69.6 |
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| 10^9/Liter | SB-497115-GR |
|---|---|
| Baseline | 16.5 ± 8.45 |
| Day 8 | 23.0 ± 16.77 |
| Day 15 | 41.5 ± 48.32 |
| Day 22 | 41.0 ± 41.80 |
| Day 29 | 55.3 ± 45.75 |
| Day 36 | 78.1 ± 72.76 |
| Day 43 | 78.0 ± 88.31 |
| Week 10 | 88.9 ± 81.15 |
| Week 14 | 121.6 ± 121.20 |
| Week 18 | 87.3 ± 80.09 |
| Week 22 | 78.5 ± 57.58 |
| Week 26 | 86.2 ± 49.62 |
Change from baseline was calculated as values at Days 8, 15, 22, 29, 36, and 43 and Weeks 10, 14, 18, 22, and 26 minus baseline value. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| 10^9/Liter | SB-497115-GR |
|---|---|
| Day 8 | 6.4 ± 13.53 |
| Day 15 | 25.1 ± 46.73 |
| Day 22 | 24.6 ± 39.37 |
| Day 29 | 38.9 ± 42.37 |
| Day 36 | 61.7 ± 69.53 |
| Day 43 | 61.6 ± 86.72 |
| Week 10 | 71.4 ± 80.01 |
| Week 14 | 104.5 ± 120.20 |
| Week 18 | 69.4 ± 80.23 |
| Week 22 | 61.1 ± 54.85 |
| Week 26 | 68.4 ± 46.49 |
Maximum duration is measured as the longest period (days) for which a participant continuously maintained platelet counts within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Days | SB-497115-GR |
|---|---|
| Mean Maximum Duration for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter | 59.5 ± 46.99 |
Total time is measured as the cumulative number of days over which platelet counts were maintained within the target range (\>=50 x 10\^9/Liter and \<=400 x 10\^9/Liter). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Days | SB-497115-GR |
|---|---|
| Mean Total Time for Which Participants Maintained Platelet Counts >=50 x 10^9/Liter and <=400 x 10^9/Liter | 78.4 ± 54.56 |
When abnormal bleeding(s) was found since the last visit, it was recorded as a bleeding episode(s). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Percentage of participants | SB-497115-GR |
|---|---|
| Day 1 | 48 |
| Day 8 | 35 |
| Day 15 | 27 |
| Day 22 | 36 |
| Day 29 | 18 |
| Day 36 | 23 |
| Day 43 | 27 |
| Week 10 | 11 |
| Week 14 | 14 |
| Week 18 | 26 |
| Week 22 | 28 |
| Week 26 | 5 |
ITP medications are drugs, such as steroids or immunoglobulin, to be used for ITP. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Percentage of participants | SB-497115-GR |
|---|---|
| Percentage of Participants With a Reduction in Dose and/or Number of Drugs of Concomitant ITP Medications From Baseline | 36.8 |
Rescue treatment for ITP is treatment applied to participants at high bleeding risk, such as those undergoing platelet transfusion or dose increase of steroids. Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Percentage of participants | SB-497115-GR |
|---|---|
| Percentage of Participants Who Received Rescue Treatment for ITP | 9 |
Cumulative number of days for which a participant received ITP medication during the treatment/total treatment period (months). Participants receiving placebo in the double-blind phase received SB-497115-GR in the open-label phase for up to 26 weeks. Participants receiving SB-497115-GR in the double-blind phase for 7 weeks continued to receive SB-497115-GR in the open-label phase for 19 weeks. The data from these two groups were pooled as a 26 week treatment of SB-497115-GR group and analyzed for the efficacy and safety.
| Days | SB-497115-GR |
|---|---|
| Mean Number of Days of Concomitant ITP Medication Use Per Month | 25.14 ± 11.796 |
Cmax: Peak plasma concentration of SB-497115
| ng/mL (nanograms/milliliter) | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| Pharmacokinetics of SB-497115-GR, Cmax | 2992.4 ± 1253.14 | 6776.4 ± 2619.62 | 11877.8 ± 3926.21 |
tmax: Time when Cmax was achieved
| Hours | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| Pharmacokinetics of SB-497115-GR, Tmax | 3.192 (2.00 to 4.17) | 4.000 (2.00 to 4.00) | 2.967 (1.92 to 4.17) |
t1/2 is half life based on the terminal phase
| Hours | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| Pharmacokinetics of SB-497115, t1/2 | 19.50 ± 7.164 | 29.96 ± 7.664 | 18.19 ± 4.938 |
Lambda z is first order rate constant associated with the terminal portion of the plasma concentration curve.
| 1/hour | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| Pharmacokinetics of SB-497115-GR, Lambda z | 0.04021 ± 0.015558 | 0.02724 ± 0.006881 | 0.04040 ± 0.011422 |
AUC is area under a concentration vs. time curve. AUC0-24 (Area under the plasma concentration-time curve between 0 to 24 hrs) is calculated using the following equation: AUC0-24= AUClast + Clast × (1 - e-λz × \[24-tlast\])/λz. AUClast is AUC (area under a curve) computed to the last observation. Clast is concentration of last observation.
| hr*ng/mL | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| AUClast | 41671.5 ± 24344.64 | 92556.2 ± 41095.63 | 171523.2 ± 75250.93 |
| AUC0-24 | 41637.2 ± 24361.51 | 92527.5 ± 41122.30 | 171551.0 ± 75242.59 |
CL/F: CL is an estimate of the total body clearance, and F is the fraction of dose absorbed.
| L/hr (Liters/hour) | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| Pharmacokinetics of SB-497115-GR, CL/F | 0.37156 ± 0.154284 | 0.30923 ± 0.114096 | 0.33035 ± 0.124401 |
VZ/F: VZ is the volume of distribution based on the terminal phase, and F is the fraction of dose absorbed.
| Liters | SB-497115-GR 12.5 mg | SB-497115-GR 25 mg | SB-497115-GR 50 mg |
|---|---|---|---|
| Pharmacokinetics of SB-497115-GR, Vz/F | 5.6267 ± 2.00964 | 5.3870 ± 1.75077 | 5.0391 ± 1.76091 |
Collected over AE data were collected from the beginning of the double-blind (DB) phase. In the Long-Term (LT) phase, AEs were pooled from all participants (pts) who started the DB phase, regardless of whether they completed the phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Short-Term (Double-Blind) Phase | — | 0/8 (0%) | 2/8 (25%) |
| SB-497115-GR Short-Term (Double-Blind) Phase | — | 1/15 (6.7%) | 7/15 (46.7%) |
| SB-497115-GR Long-Term Phase | — | 6/23 (26.1%) | 19/23 (82.6%) |
| Event | Placebo Short-Term (Double-Blind) Phase | SB-497115-GR Short-Term (Double-Blind) Phase | SB-497115-GR Long-Term Phase |
|---|---|---|---|
| Hemorrhagic diathesisBlood and lymphatic system disorders | 0/8 | 0/15 | 2/23 |
| Transient ischemic attackNervous system disorders | 0/8 | 1/15 | 1/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/8 | 0/15 | 1/23 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/15 | 1/23 |
| Renal impairmentRenal and urinary disorders | 0/8 | 0/15 | 1/23 |
| Event | Placebo Short-Term (Double-Blind) Phase | SB-497115-GR Short-Term (Double-Blind) Phase | SB-497115-GR Long-Term Phase |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/8 | 4/15 | 10/23 |
| Alanine aminotransferase increasedHepatobiliary disorders | 0/8 | 3/15 | 4/23 |
| Aspartate aminotransferase increasedHepatobiliary disorders | 0/8 | 1/15 | 3/23 |
| HeadacheNervous system disorders | 1/8 | 1/15 | 3/23 |
| CataractEye disorders | 1/8 | 0/15 | 0/23 |
| CystitisInfections and infestations | 0/8 | 0/15 | 2/23 |
| GastroenteritisInfections and infestations | 0/8 | 1/15 | 2/23 |
| Herpes simplexInfections and infestations | 0/8 | 0/15 | 2/23 |
| RhinitisInfections and infestations | 0/8 | 0/15 | 2/23 |
| NauseaGastrointestinal disorders | 0/8 | 1/15 | 2/23 |
| Age Continuous(years) | SB-497115-GR | Placebo | Total |
|---|---|---|---|
| Mean | 53.7 ± 13.72 | 58.4 ± 11.72 | 55.3 ± 12.98 |
| Sex: Female, Male(Participants) | SB-497115-GR | Placebo | Total |
|---|---|---|---|
| Female | 8 | 7 | 15 |
| Male | 7 | 1 | 8 |
| Race/Ethnicity, Customized(participants) | SB-497115-GR | Placebo | Total |
|---|---|---|---|
| Japanese Heritage | 15 | 8 | 23 |
The record gives a start of Sep 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →